🇺🇸 FDA
Patent

US 12090201

Methods for treating atopic dermatitis by administering an IL-4R antagonist antibody

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 12090201 (Methods for treating atopic dermatitis by administering an IL-4R antagonist antibody) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K2039/505, A61K2039/545, A61K2039/55, A61K39/3955